Peter C. Brandt - Oct 4, 2024 Form 4 Insider Report for IN8BIO, INC. (INAB)

Role
Director
Signature
/s/ Jason Minio, Attorney-in-Fact
Stock symbol
INAB
Transactions as of
Oct 4, 2024
Transactions value $
$0
Form type
4
Date filed
10/8/2024, 04:15 PM
Previous filing
Jun 14, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INAB Common Stock Award +253K +95.74% 518K Oct 4, 2024 Direct F1
holding INAB Common Stock 105K Oct 4, 2024 See footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INAB Series A Warrants (right to buy) Disposed to Issuer -82K -100% 0 Oct 4, 2024 Common Stock 82K $1.25 Direct F3, F4, F5
transaction INAB Series A Warrants (right to buy) Award +82K 82K Oct 4, 2024 Common Stock 82K $0.45 Direct F3, F4, F5
transaction INAB Series C Warrants (right to buy) Award +253K 253K Oct 4, 2024 Common Stock 253K $0.27 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities are included within 253,164 Issuer Units purchased by the Reporting Person for $0.395 per Unit. Each Unit consists of one share of common stock and one Series C warrant representing the right to purchase 253,164 shares of common stock.
F2 The securities are held by The Peter C. Brandt 2020-4 GRAT (the "GRAT"). The Reporting Person is the trustee of the GRAT and, as such, has voting and investment power over the shares held by the GRAT.
F3 The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.25 and expiration date of June 13, 2025. The exercise price was reduced to $0.45 and the warrant expiration date was extended to October 4, 2025.
F4 Fully vested and exercisable.
F5 The reported securities are included within 81,967 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock.